Los Angeles

About

Nearly 600 life science companies call Los Angeles County home, as well as world class universities, teaching hospitals and biomedical research institutes. LA County also receives almost $1B in NIH funding each year, a testament to the great research ongoing in the region.

Even with its broad resources and assets, the greater Los Angeles life science industry represents many challenges unique to the area, including a wide geographical distribution, a lack of sufficient capital investment in this industry, limited wet lab space, and the migration of new companies and talent to established life science clusters such as San Diego and San Francisco.

Biocom aims to solve these issues by fostering growth, networking, and accelerating life sciences in the Los Angeles region while giving member companies access to unrivaled opportunities such as out-of-area capital, discount purchasing programs, workforce development, and advocacy support.

History

Biocom’s Los Angeles office opened in 2016 following a partnership with the LA County Economic Development Corporation (LAEDC) and others to respond to LA County’s need for a life science industry Implementation Plan for the region. The results of this effort and the desire of our existing LA-area members for the benefits offered by a more unified regional cluster, made it clear that a local presence was needed.

In its first year, Biocom’s Los Angeles-dedicated team launched dozens of initiatives, events, and programming to help bring the Los Angeles life science community closer together and support the growing ecosystem.

Los Angeles Advisory Board

Bill Allen
Bill Allen

Bill Allen is the Chief Executive Officer of the Los Angeles County Economic Development Corporation and its subsidiary, the World Trade Center Los Angeles. Mr. Allen is also Co-Chair of the California Stewardship Network, a Vice Chair of the Economic Alliance of the San Fernando Valley and a member of the Board of Directors of the Weingart Foundation, Regional Economic Association Leaders of California Coalition, Los Angeles Area Chamber of Commerce, Los Angeles Coalition for the Economy and Jobs, Film L.A., Unite L.A., and Sister Cities of Los Angeles.

Active in regional economic development for more than twenty years, Mr. Allen was the first CEO of the Economic Alliance of the San Fernando Valley from 1996-2000, and in 2000 was named California’s Civic Entrepreneur of the Year by the California Center for Regional Leadership. Mr. Allen has served as a trustee of the University of Southern California, chair of the Creative Arts Emmy Awards for the Academy of Television Arts and Sciences, Chair of Film LA, and cochair of the “Shaping Tomorrow” capital campaign for the Valley Presbyterian Hospital, on whose board he served for fifteen years.
Mr. Allen was previously a television network and studio executive with nearly twenty years experience in entertainment production and management, where he supervised the development and production of hundreds of episodes of network, syndicated and cable television, as well as several highly rated TV movies and specials. A cum laude graduate of the School of Cinematic Arts at the University of Southern California in 1979, Mr. Allen also received his Masters Degree in Business Administration from Pepperdine University in 1983.

Jason Crockett
Jason Crockett

Jasson Crockett joined Mayor Eric Garcetti’s Office of Economic Development in 2016, where he manages business development efforts in the life science and healthcare sectors, sports, and tax policy. Jasson works to connect companies of all sizes to resources within City Hall to enable their growth in the City of LA, and develop a more connected ecosystem wherein companies can thrive.

Prior to joining the Mayor’s Office, Jasson worked with a national consulting firm, specializing in strategic financial management consulting for nonprofit organizations. Additionally, Jasson has experience as a teacher and case manager for a nonprofit organization located in South-Los Angeles. Jasson holds a Bachelor’s degree from Georgetown University where he majored in Finance and Management.

Bassil Dahiyat
Bassil Dahiyat

Bio coming soon.

DeeDee Deman
DeeDee Deman

DeeDee is the Founder, Chairman and Chief Executive Officer of Bench International. Bench established in 1974, will be celebrating its 43rd anniversary December, 2017. Bench is the oldest and largest global, woman-owned retained executive recruiting, talent mapping and consulting organization serving the Life Science sector. DeeDee guides and directs a global team of 25 recruiting executives and scientific leaders who are defining/ redefining game-changers themselves, committed to extraordinary vision and execution in extraordinary times. Bench operates as one global integrated team with multiple sites throughout the world. As part of “give back” to the sector DeeDee and her team support and coach today’s leaders, providing high level insights on leadership and trends.

DeeDee leverages her 40+ years of Life Science industry focus by guiding her team on the execution and working with companies to, “do more with fewer”. With the global search access as well as their ability to map and track talent Bench’s clients and investors are provided with Best Practice and Best Knowledge of the industry leadership talent, that provides companies with the differentiators necessary for healthy building of larger companies, or to build smaller companies to achieve the critical inflection points they desire. With an indefatigable, pioneering and entrepreneurial spirit, DeeDee has taken Bench from its founding in 1974 to its eminence today as one of the most successful companies "shattering" diversity ceilings bringing women, people of color, those who “think and “do,” differently to leadership roles in life science companies.

In 2009 DeeDee was the first executive recruiter to be named “1 of the Top 100 Most Inspiring Leaders” by PharmaVOICE Magazine, a Hall of Fame Inductee of the National Association of Women Business Owners (NAWBO). “Giving Back” being cause-motivated, is critical to DeeDee. She has served for 15 years as a member of the board of Learning Forum International (LFI), Making Great Kids Greater through student and educator programs that contribute to the mastery of learning and life skills by today's youth, leading to their academic, personal and professional success. Her prior not for profit board commitments have included founding the Forum for Global Pharmaceutical Diversity and Inclusion (FRXDI), serving as a member of the board for the Los Angeles Chapter the Isreal International Cancer Research Fund (ICRF), Family Promise, Healthcare Business Woman’s Association’s (HBA’s) Northern California Chapter and Europe Chapter. DeeDee holds a double Masters of Science degree, Auditory Pathology and Speech Pathology. Prior to founding Bench International, DeeDee served as a Research Fellow in a joint research program sponsored by National Institute of Health (NIH) and Siemens Corporation, the University of California, San Diego, State Diego State University and the San Diego Speech and Hearing Center.

Steve Fiacco
Steve Fiacco

Bio coming soon.

Scott Fraser
Scott Fraser

Professor Scott E. Fraser has a long-standing commitment to quantitative biology, applying the tools of chemistry, engineering, and physics to problems in biology and medicine. His personal research centers on imaging and molecular analyses of intact biological systems, with an emphasis on studies of early animal development, organogenesis, and medical diagnostics.

After receiving training in physics (BS, Harvey Mudd College, 1976) and biophysics (PhD, Johns Hopkins University, 1979), Fraser joined the faculty at UC Irvine, and rose through the ranks to become Chair of the Department of Physiology and Biophysics. In 1990 he moved to Caltech to serve as the Anna L. Rosen Professor of Biology, and the Director of the Biological Imaging Center. He is deeply committed to interdisciplinary training and translational research, having helped to found the Caltech Brain Imaging Center and the Kavli Institute of Nanoscience, as well as serving as the Director of the Rosen Center for Biological Engineering.

To foster the translation of basics science research findings to application in clinical practice, Fraser has actively collaborated with clinicians in fields ranging from cardiology to ophthalmology. Such interactions have helped translate his 80 issued patents to FDA approved tests, novel research tools, and start-up companies. In Fall 2012, Fraser moved to USC to take a Provost Professorship in the Dornsife College of Letters Arts and Sciences, the Children’s Hospital Los Angeles, Keck School of Medicine and the Viterbi School of Engineering. He remains active in interdisciplinary research and serves as the Director of Science Initiatives for the USC campuses.

Judy Gasson
Judy Gasson

Dr. Gasson has spent more than 30 years at UCLA in various teaching, research and senior leadership roles. She currently serves as Director of the David Geffen School of Medicine Technology Accelerator, a role that she has held since November, 2015 and as a Director of UCLA Technology Development Corporation. In this capacity, she works with faculty inventors, business students and faculty, and the Office Technology Development to facilitate the translation of innovative discoveries to address unmet medical needs.

She served as the Director of UCLA's Jonsson Comprehensive Cancer Center (JCCC) from September 1995 until September 2015. JCCC is one of only 47 institutions designated as comprehensive cancer centers by the National Cancer Institute, and consistently rated among the nation’s top ten institutions, according to U.S. News & World Report. Under her leadership, JCCC became an international pioneer in “translating” laboratory discoveries into more effective new therapies for cancer patients everywhere. She also served as the President of the Jonsson Cancer Center Foundation. Dr. Gasson also served as Senior Associate Dean for Research at the David Geffen School of Medicine from September, 2012 until she retired three years later. She began her career at UCLA in 1983 as a Professor of Medicine (Hematology-Oncology) and Biological Chemistry. Her work was instrumental in purifying for the first time a hormone-like substance that increases the speed of bone marrow cell reproduction. That substance, called GM-CSF, also had impacts on the granulocytes and monocytes of the immune system. Her academic credentials include a BS degree in Microbiology from Colorado State University and a Doctorate in Physiology from the University of Colorado. She did her post-doctorate work at the Salk Institute in La Jolla, studying glucocorticoid hormones.

Joseph Panetta
Joseph Panetta

President and Chief Executive Officer, Member, Biocom Board of Directors -- San-Diego As the leading advocate for the life science industry in California, President and CEO Joe Panetta guides a robust organization of nearly 1000 members, setting strategic direction, guiding policy priorities, and championing the biopharmaceutical industry at the local, state, national, and international level. Mr. Panetta holds a Bachelor of Science degree in biology from LeMoyne College, and a Master of Public Health degree in industrial and environmental health from the University of Pittsburgh. He is a graduate of the Brookings Institution Program for Executives and the Harvard Program on Negotiation.

Alice Jacobs, M.D.
Alice Jacobs, M.D.

Alice Jacobs, M.D. BioLabs Advisor, Caltech EIR, Third Rock Ventures Dr. Jacobs serves as EIR at Caltech and as an advisor to Biolabs, FiNC Technologies, Third Rock Ventures/MIT/Bob Langer, GE Healthcare Ventures, Greybird Ventures and Essex Management. Advisory/investor roles include artificial intelligence/machine learning/big data in digital health/wellness, microbiome, clean energy, synthetic biology, genomics, liquid biopsy and other precision medicine technologies, drug discovery/development platforms and gene editing. This includes a platform technology in the top 10 recommendations of the Blue Ribbon Panel on the cancer moonshot to speed progress in cancer.

While still a student at Harvard Medical School, Dr. Jacobs co-founded IMDx along with Dr Boris Nikolic (Chief Science and Technology Advisor to Bill Gates and Managing Director, Biomatics Capital.) IMDx became an industry leader globally in the development and manufacturing of molecular diagnostic tests, prior to exit.

Dr. Jacobs holds multiple patents in personalized medicine and has received numerous awards including being recognized by Scientific American as one of the top 50 innovators and by the World Economic Forum as a Young Global Leader, a 40 under 40 award by the Boston Business Journal as well as for Healthcare Innovation in Clinical Diagnostics by Frost & Sullivan. She holds a BA in Art History, a BS in Biological Sciences from Stanford with Honors in Developmental Neurobiology and an MD from Harvard Medical School.

Seth Levy
Seth Levy

As managing partner of the Los Angeles office and co-chair of the firm’s Life Sciences group, Seth focuses his practice on intellectual property protection and commercial transactions in life sciences and healthcare. Seth works with clients to implement strategies for international intellectual property protection and enforcement, to structure business relationships around the development and commercialization of life sciences technologies, and to support clinical research programs for both nonprofit and for-profit clients. Seth has significant experience working with academic and healthcare institutions to develop and support their technology transfer programs. He also serves as outside general counsel to emerging growth companies, oftentimes those that do business with academic and healthcare institutions.

A graduate of Cornell University with a B.S., cum laude, in Agricultural & Biological Engineering, and a J.D. from USC Law School, Seth presents nationally and internationally on emerging intellectual property issues, and has received numerous awards and recognitions for his leadership and work in the life sciences, intellectual property and legal communities.

Peter Moglia
Peter Moglia

Peter M. Moglia has served as Chief Investment Officer of Alexandria Real Estate Equities, Inc. since January 2009, and has been with the Company serving in a number of capacities since April 1998. From April 2003 through 2008, Mr. Moglia was responsible for the management of the Company’s Seattle asset base and operations. From 1998 to 2003, Mr. Moglia’s responsibilities were focused on underwriting, acquisitions, and due diligence activities.

Prior to joining the Company, Mr. Moglia served as an Analyst for Lennar Partners, Inc., a diversified real estate company, where his responsibilities included underwriting and structuring direct and joint venture real estate investments. Mr. Moglia began his real estate career in the Management Advisory Services group within the E&Y Kenneth Leventhal Real Estate Group, Ernst & Young, LLP where he spent six years providing valuation, feasibility, financial modeling, and other analytical services to a number of real estate developers, financial institutions, pension funds, and government agencies. Mr. Moglia received his Bachelor of Arts degree in Economics from the University of California at Los Angeles.

Jon Thomas
Jon Thomas

Jonathan Thomas (“JT”) has been Chair of the governing Board since June 2011. Prior to that he was a Co-Founding Partner at Saybrook Capital (“Saybrook”), an investment banking and private equity firm based in Santa Monica, California. Long interested in the biological sciences, JT majored in Biology and History at Yale, where he graduated summa cum laude. As a George C. Marshall Scholar at Oxford, he then earned a PhD with a medical focus in Commonwealth History. He subsequently returned to Yale for a JD at the Yale Law School. While there, he retained an involvement with biology by teaching courses on the legal implications of genetic engineering and the impact of disease on history.

He went on to be an investment banker for Ehrlich Bober & Co. (a top-10 Wall Street public finance firm) where, among other things, he led a team that underwrote over $1 billion in various kinds of bonds for the Los Angeles Community College District. He left Ehrlich Bober in 1990 to co-found Saybrook. While with Saybrook, he led an early round of financing for Advanced Cell Technology (now Ocata Therapeutics), which now has two embryonic stem cell-based clinical trials in progress. In addition to his financing expertise, JT brings legal expertise to help CIRM navigate clinical trials, bilateral collaborative agreements, intellectual property, loan agreements and other legal challenges that confront CIRM on an ongoing basis. His legal experience includes clerking for White House Counsel Lloyd Cutler in the last year of the Carter Administration and also for the Honorable George Mackinnon of the United States Circuit Court of Appeals for the District of Columbia Circuit. He later practiced at then-Munger, Tolles & Rickershauser in Los Angeles.

JT also has a broad knowledge of governmental agencies, having served for seven years each as either member or vice president of the City of Los Angeles Board of Harbor Commissioners and as a member of the Governing Board for the Alameda Corridor Transportation Authority. In that latter role, he developed a plan to finance the $2.4 billion expansion of the Corridor rail lines from the Ports of Los Angeles and Long Beach to downtown Los Angeles. Through this government work and his many years in public finance, he has served at various times as underwriter, financial advisor and issuer of a wide range of tax-exempt and taxable bonds. JT has worked closely with political officials at the federal, state and local level on a variety of projects for over 30 years. He was the chief government liaison to the Governor and State legislature for the Official Committee of Unsecured Creditors in the PG&E bankruptcy, for whom Saybrook acted as financial advisor in their Chapter 11 proceedings. He has structured a number of public/private partnerships, including the financing for the Dolby (formerly Kodak) Theatre in Hollywood, home to the Academy Awards.

JT has a long-standing commitment to patient advocacy. He spent more than 15 years on the Board of the Crippled Children’s Society of Southern California and served as Chair for four years. The organization, now called AbilityFirst, assists children with spinal cord injuries and mental disabilities that could be targets of stem cell therapies. He is an Honorary member of the AbilityFirst Board.

Dr. Martin Zagari
Dr. Martin Zagari

Dr. Martin Zagari is Vice President of Global Health Economics at Amgen. In this role, he directs the planning, execution and scientific dissemination of worldwide economic and value evidence for Amgen’s entire product portfolio from early stage molecules to marketed products. Dr. Zagari joined Amgen in May of 2005. Prior to Amgen, between 1997 and 2005, Dr. Zagari held various positions at Johnson & Johnson in Health Economics, Medical Affairs, and Strategic Marketing. These positions included: Executive Director in J&J Corporate Strategic Marketing for the erythropoietic agents, Medical Director for erythropoietic treatments in oncology at Ortho Biotech, and Director positions in Health Economics. Between 1994 and 1997, Dr. Zagari worked in Health Economics and Outcomes consulting at Technology Assessment Group/Lewin-TAG, based in San Francisco. Martin received his MD from Stanford University, an MBA from Rutgers University, and BS in Biology from the University of North Carolina at Chapel Hill and is trained in anesthesiology.

Featured Members

Biocom is a member-driven organization that provides life science companies with the opportunities and resources they need to fulfill business goals and improve life through health, energy and agricultural advancements.

Biocom is a trusted partner in connecting Los Angeles life science companies with unique opportunities. Biocom's Los Angeles area members are focused on sectors including biotechnology, pharmaceuticals, diagnostics, medical devices, digital health, health IT, agriculture and bio-renewable energy.

"With our L.A. office, we continue our tradition of accelerating cluster development across the state. Our expanded staff bolsters the work we do in many areas, including political advocacy, cluster-specific events, capital development programs and workforce development. Every member of our team is motived by the vast potential for a thriving industry in Los Angeles and is working to give members the tools and voice they need to succeed." – Joe Panetta, president and CEO of Biocom

Download a full member directory here (available only to Biocom members).

Featured Initiatives

Biocom’s Los Angeles initiatives are targeted programs that address specific needs presented by the Los Angeles life science community and are tailored to the region’s unique requirements and attributes.

Initiatives include partnerships with local public officials, community engagement organizations, as well as member companies.

“The life science industry in L.A. is an exciting place to be today. We are fortunate to have the best and brightest working with us at Biocom to drive the success of this region. In addition to our team, we benefit from the strong partnerships we’ve forged with the Los Angeles Economic Development Corporation, the Los Angeles Venture Association and other organizations that share in our enthusiasm for and commitment to life science in the greater Los Angeles area.” – Dina Lozofsky, Executive Director, Biocom Los Angeles

All Los Angeles initiatives are fully vetted and informed by board members, committees, and member companies.

Catalyst Awards
Catalyst Awards

Biocom recently expanded the Biocom Catalyst Awards to Los Angeles. The Catalyst awards are an annual celebration of the most inspiring and driven life science leaders who are making their mark on the industry before their 40th birthday. View Awards

Capital Development
Capital Development

Biocom proudly brings Biocom’s Capital Development programs to our Los Angeles members. Today, Los Angeles startups can enjoy Biocom’s full suite of programs aiming to connect startups with the resources they need. Learn More

Building a Nucleus
Building a Nucleus

Since its opening in 2016, Biocom’s Los Angeles office has brought together over 100 member companies as well as public officials and community organizations in the Los Angeles region to fuel growth, revenue, and job creation in the area by solving problems presented by issues like fragmented clusters and lack of access to wet lab space. View article
In 2017, Propel L.A. named Biocom a Lead Partner in their plan to accelerate economic growth in Los Angeles. The plan brings together 18 total Lead Partners, the Los Angeles Economic Development Committee, and Propel L.A. to help "acheive shared economic prosperity, social equity, and harness the region's innovation-intensive industries." Read the full press release and learn more about Propel L.A. here.

The 2017 Biocom California Economic Impact Report found that the Los Angeles biosciences industries have grown by more than 11.2 percent in the past five years, and have generated more than $40 billion in total economic output in the last year. View article

$40 Billion and Growing
$40 Billion and Growing

The 2017 Biocom California Economic Impact Report found that the Los Angeles biosciences industries have grown by more than 11.2 percent in the past five years, and have generated more than $40 billion in total economic output in the last year. View article

Los Angeles Startup Resources Committee
Los Angeles Startup Resources Committee

The Los Angeles Startup Resources Committee supports the growing early-stage ecosystem in the greater Los Angeles region, while providing opportunities for committee members to meet other area professionals, keep current on issues affecting the local industry, and share best practices. Learn More

To learn more about Biocom’s Los Angeles mission, or to ask us a question, send us a message.

 

Los Angeles Office

444 S. Flower St., Suite 1780
Los Angeles, CA 90071
(213) 943-2920
biocomla@biocom.org

 
 

Stay in the know with the Biocommunique

Sign up for Biocom's bi-weekly newsletter to get all the latest life science news sent directly to your inbox.